Abstract: A process for producing a metallic structure by additive manufacturing comprises: providing a deposition-receptive substrate comprising a profiled surface, the profiled surface comprising a plurality of recessed and/or protruding surface features having elongated non-vertical walls and a depth of at least 0.

Abstract: A process for absorbing carbon dioxide from a gas stream containing carbon dioxide, including the steps of contacting the gas stream with an aqueous composition including a substituted heteroaromatic compound having a six-membered heteroaromatic ring with from 1 to 3 nitrogen atoms in the heteroaromatic ring and at least one substituent wherein at least one of the substituents is of formula —R1NH2 wherein R1 is selected from C1 to C6 alkylene and ethers of formula —R2—O—R3— wherein R2 and R3 are C1 to C3 alkylene.

Abstract: The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject. The methods and systems provided enable a quantitative assessment and theoretical predictions of neocortical amyloid loading or amyloid beta levels based on the measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).

Abstract: The present inventors have identified a panel of biomarkers present in a biological sample of an individual (e.g. blood, including serum or plasma) whose concentrations or levels are altered in individuals with a neurological disorder. Accordingly, changes in the level of any one or more of these biomarkers can be used to assess cognitive function, to diagnose or aid in the diagnosis of a neurological disorder and/or to monitor a neurological disorder in a patient (e.g., tracking disease progression in a patient and/or tracking the effect of medical or surgical therapy in the patient). Changes in the level of any one or more of these biomarkers can also be used to stratify a patient (i.e., sorting an individual with a probable diagnosis of a neurological disorder or diagnosed with a neurological disorder into different classes of the disorder) and diagnosing or aiding in the diagnosis of mild cognitive impairment (MCI) as well as diagnosing or aiding in the diagnosis of cognitive impairment.